{"article":{"annotation":{"article_id":"brazil-anvisa-bans-irregular-medicines-october-2026","available_at":"2026-10-12T09:41:13.312594Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"fcc5d3df1bb9d906b2afbf184cd3c33491d692bed7dffd99fc4f9e11489644e7","input_sha256":"84c77bb6fc89b5b4b5d6e3988ba3f7db1fcbcdb62002596a16975f03c11a4e89","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"BR","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"geometry":null,"id":"iso3166-1:BR","kind":"country-or-area","labels":{"ar":"البرازيل","en":"Brazil","es":"Brasil","fr":"Brésil"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=es","category":"health","content":{"key_points":[],"paragraphs":["El regulador sanitario de Brasil, Anvisa, prohibió la venta de varios medicamentos irregulares el 6 de octubre. Las medidas abarcan insulina glargina distribuida por una empresa sin autorización, un medicamento compuesto comercializado al público sin receta y péptidos sin registro.","Anvisa también informó del retiro voluntario por el fabricante de un lote de Imaavy y ordenó retirar un lote del antibiótico Lizbi tras confirmar pérdida de esterilidad por daños en el envase. Este artículo informa sobre medidas regulatorias y no es un consejo de tratamiento individual."],"sections":[]},"corrections":[{"at":"2026-10-07T00:55:00+03:00","language":"es","text":"Se añadieron a este artículo las ediciones alemana y portuguesa y las traducciones de las explicaciones de datos y correcciones."},{"at":"2026-10-12T06:25:46+03:00","language":"es","text":"Se añadieron las traducciones completas de las celdas de texto de las tablas en los siete idiomas. Se conservaron los valores originales de las fuentes y las observaciones numéricas."},{"at":"2026-10-12T06:25:47+03:00","language":"es","text":"Se corrigió la redacción de las ediciones lingüísticas de este artículo para conservar toda su información y su alcance."}],"country":"BR","data":{"blocks":[{"columns":[{"key":"item","label":{"ar":"المنتج أو الفئة","de":"Produkt oder Kategorie","en":"Product or category","es":"Producto o categoría","fr":"Produit ou catégorie","pt":"Produto ou categoria","tr":"Ürün veya kategori"},"language":"en","type":"text"},{"key":"action","label":{"ar":"إجراء أنفيسا","de":"Maßnahme von Anvisa","en":"Anvisa action","es":"Medida de Anvisa","fr":"Mesure de l’Anvisa","pt":"Medida da Anvisa","tr":"Anvisa işlemi"},"language":"en","type":"text"}],"description":{"ar":"فئات المنتجات وأنواع الإجراءات في إعلان أنفيسا بتاريخ 6 أكتوبر 2026.","de":"Produkte und Maßnahmen in der Mitteilung von Anvisa vom 6. Oktober 2026.","en":"Products and action types in Anvisa’s October 6, 2026 notice.","es":"Productos y tipos de medidas del aviso de Anvisa del 6 de octubre de 2026.","fr":"Produits et types de mesures dans l’avis de l’Anvisa du 6 octobre 2026.","pt":"Produtos e tipos de medida no comunicado da Anvisa de 6 de outubro de 2026.","tr":"Anvisa’nın 6 Ekim 2026 duyurusundaki ürün grupları ve karar türleri."},"id":"brazil-anvisa-regulatory-actions","methodology":{"ar":"يلخص الجدول نطاق الإعلان وفق نص المصدر؛ ولا يقدم إرشاداً طبياً.","de":"Die Tabelle fasst den Umfang der Mitteilung mit den Begriffen der Quelle zusammen und enthält keine medizinische Beratung.","en":"The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance.","es":"La tabla resume el alcance del aviso según el texto fuente; no ofrece orientación médica.","fr":"Le tableau résume le champ de l’avis selon le texte source ; il ne fournit pas de conseil médical.","pt":"A tabela resume o escopo do comunicado nos termos da fonte; não fornece orientação médica.","tr":"Tablo karar kapsamını kaynak metindeki ifadelerle özetler; listelenen ilaçlar için tıbbi öneri içermez."},"rowTranslations":[{"action":{"ar":"حُظر بيع جميع الدفعات؛ ولم تكن جهة التوزيع مرخصة.","de":"Der Verkauf aller Chargen ist verboten; der Vertrieb hatte keine Genehmigung.","en":"Sale of all lots prohibited; distributor lacked authorization.","es":"Prohibida la venta de todos los lotes; el distribuidor carecía de autorización.","fr":"Vente de tous les lots interdite ; le distributeur n’était pas autorisé.","pt":"A venda de todos os lotes foi proibida; o distribuidor não tinha autorização.","tr":"Tüm lotların satışı yasaklandı; dağıtım şirketinin yetkisi yoktu."},"item":{"ar":"إنسولين غلارجين 3 mL/100 IU، Costa Mar","de":"Insulin glargin 3 mL/100 IU, Costa Mar","en":"Insulin glargine 3 mL/100 IU, Costa Mar","es":"Insulina glargina 3 mL/100 IU, Costa Mar","fr":"Insuline glargine 3 mL/100 IU, Costa Mar","pt":"Insulina glargina 3 mL/100 IU, Costa Mar","tr":"İnsülin glarjin 3 mL/100 IU, Costa Mar"}},{"action":{"ar":"حُظر البيع والتوزيع والإعلان؛ واستندت الهيئة إلى تسويق دواء مركّب موحّد وغير مخصص لفرد بعينه دون وصفة طبية.","de":"Verkauf, Vertrieb und Werbung verboten; die Behörde verwies auf die Vermarktung eines standardisierten, nicht patientenindividuell hergestellten Rezepturarzneimittels ohne Verschreibung.","en":"Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.","es":"Prohibidas la venta, distribución y publicidad; el regulador señaló la comercialización sin receta de un medicamento compuesto estandarizado y no individualizado.","fr":"Vente, distribution et publicité interdites ; l’autorité a invoqué la commercialisation sans ordonnance d’un médicament composé standardisé et non individualisé.","pt":"Venda, distribuição e publicidade proibidas; o órgão regulador citou a comercialização sem receita de medicamento manipulado padronizado e não individualizado.","tr":"Satış, dağıtım ve tanıtım yasaklandı; düzenleyici kurum, kişiye özel hazırlanmayan standart bir bileşik ilacın reçete olmadan pazarlanmasını gerekçe gösterdi."},"item":{"ar":"دواء Vermefree مُركّب، Sintonia Pharma","de":"Rezepturarzneimittel Vermefree, Sintonia Pharma","en":"Vermefree compounded medicine, Sintonia Pharma","es":"Medicamento compuesto Vermefree, Sintonia Pharma","fr":"Médicament composé Vermefree, Sintonia Pharma","pt":"Medicamento manipulado Vermefree, Sintonia Pharma","tr":"Vermefree bileşik ilaç, Sintonia Pharma"}},{"action":{"ar":"حُظر البيع والتصنيع والتوزيع والإعلان والنقل والاستخدام.","de":"Verkauf, Herstellung, Vertrieb, Werbung, Transport und Verwendung sind verboten.","en":"Sale, manufacture, distribution, advertising, transport and use prohibited.","es":"Prohibidos la venta, fabricación, distribución, publicidad, transporte y uso.","fr":"Vente, fabrication, distribution, publicité, transport et utilisation interdits.","pt":"Venda, fabricação, distribuição, publicidade, transporte e uso proibidos.","tr":"Satış, üretim, dağıtım, tanıtım, taşıma ve kullanım yasaklandı."},"item":{"ar":"ببتيدات غير مسجلة واردة في البيان","de":"In der Mitteilung aufgeführte nicht registrierte Peptide","en":"Unregistered peptides listed in notice","es":"Péptidos sin registro incluidos en el aviso","fr":"Peptides non enregistrés mentionnés dans l’avis","pt":"Peptídeos não registrados listados no comunicado","tr":"Duyuruda listelenen kayıtsız peptitler"}},{"action":{"ar":"أُبلغ عن سحب طوعي؛ مع احتمال وجود جزيئات زجاجية في القوارير.","de":"Freiwilliger Rückruf gemeldet; möglicherweise befinden sich Glaspartikel in den Durchstechflaschen.","en":"Voluntary recall reported; possible glass particles in vials.","es":"Retirada voluntaria comunicada; posible presencia de partículas de vidrio en los viales.","fr":"Rappel volontaire signalé ; présence possible de particules de verre dans les flacons.","pt":"Recolhimento voluntário informado; há possibilidade de partículas de vidro nos frascos.","tr":"Gönüllü geri çağırma bildirildi; flakonlarda cam parçacıkları bulunma olasılığı var."},"item":{"ar":"دفعة Imaavy رقم JNYJ1201","de":"Charge Imaavy JNYJ1201","en":"Imaavy batch JNYJ1201","es":"Lote de Imaavy JNYJ1201","fr":"Lot Imaavy JNYJ1201","pt":"Lote de Imaavy JNYJ1201","tr":"Imaavy lotu JNYJ1201"}},{"action":{"ar":"أُمر بسحبها بعد تأكيد فقدان التعقيم المرتبط بتضرر سلامة العبوة الأولية.","de":"Rückruf angeordnet, nachdem ein mit der beeinträchtigten Unversehrtheit der Primärverpackung verbundener Verlust der Sterilität bestätigt wurde.","en":"Recall ordered after confirmed sterility loss linked to compromised primary packaging.","es":"Retirada ordenada tras confirmarse la pérdida de esterilidad vinculada al deterioro de la integridad del envase primario.","fr":"Rappel ordonné après confirmation d’une perte de stérilité liée à une atteinte à l’intégrité de l’emballage primaire.","pt":"Recolhimento determinado após a confirmação de perda de esterilidade associada ao comprometimento da integridade da embalagem primária.","tr":"Birincil ambalaj bütünlüğünün bozulmasıyla bağlantılı sterilite kaybının doğrulanmasının ardından geri çağırma emri verildi."},"item":{"ar":"دفعة Lizbi رقم 0000207107","de":"Charge Lizbi 0000207107","en":"Lizbi batch 0000207107","es":"Lote de Lizbi 0000207107","fr":"Lot Lizbi 0000207107","pt":"Lote de Lizbi 0000207107","tr":"Lizbi lotu 0000207107"}}],"rows":[{"action":"Sale of all lots prohibited; distributor lacked authorization.","item":"Insulin glargine 3 mL/100 IU, Costa Mar"},{"action":"Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.","item":"Vermefree compounded medicine, Sintonia Pharma"},{"action":"Sale, manufacture, distribution, advertising, transport and use prohibited.","item":"Unregistered peptides listed in notice"},{"action":"Voluntary recall reported; possible glass particles in vials.","item":"Imaavy batch JNYJ1201"},{"action":"Recall ordered after confirmed sterility loss linked to compromised primary packaging.","item":"Lizbi batch 0000207107"}],"sourceUrls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"],"title":{"ar":"الأدوية المحظورة أو المسحوبة","de":"Verbotene oder zurückgerufene Arzneimittel","en":"Medicines prohibited or recalled","es":"Medicamentos prohibidos o retirados","fr":"Médicaments interdits ou rappelés","pt":"Medicamentos proibidos ou recolhidos","tr":"Yasaklanan veya geri çağrılan ilaçlar"},"type":"table","updatedAt":"2026-10-12T06:25:46+03:00"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=es&format=csv","json":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=es&format=json"},"id":"brazil-anvisa-regulatory-actions"}],"data_types":["table"],"editorial_illustration":{"alt":"Ilustración conceptual de salud pública, investigación y datos conectados.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"es","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-8ff1924c-3faa-55d0-982f-f85ffe24522b","event_period":"2026-10-06","event_period_basis":"event-or-reference-period","id":"brazil-anvisa-bans-irregular-medicines-october-2026","image":null,"importance":0.6,"language":"es","modified_at":"2026-10-12T06:25:47+03:00","publication_basis":"publication-record","published_at":"2026-10-06T17:11:49+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Ilustración conceptual de salud pública, investigación y datos conectados.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"es","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"brazil-anvisa-bans-irregular-medicines-october-2026","sources":[{"checkedAt":"2026-10-06","name":"National Health Surveillance Agency of Brazil","publishedAt":"2026-10-06","url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"}],"summary":"Las prohibiciones abarcan insulina distribuida sin autorización, un producto compuesto de forma irregular y péptidos sin registro, además de dos lotes con problemas de calidad.","text":"Las prohibiciones abarcan insulina distribuida sin autorización, un producto compuesto de forma irregular y péptidos sin registro, además de dos lotes con problemas de calidad.\n\nEl regulador sanitario de Brasil, Anvisa, prohibió la venta de varios medicamentos irregulares el 6 de octubre. Las medidas abarcan insulina glargina distribuida por una empresa sin autorización, un medicamento compuesto comercializado al público sin receta y péptidos sin registro.\n\nAnvisa también informó del retiro voluntario por el fabricante de un lote de Imaavy y ordenó retirar un lote del antibiótico Lizbi tras confirmar pérdida de esterilidad por daños en el envase. Este artículo informa sobre medidas regulatorias y no es un consejo de tratamiento individual.\n\nSe añadieron a este artículo las ediciones alemana y portuguesa y las traducciones de las explicaciones de datos y correcciones.\n\nSe añadieron las traducciones completas de las celdas de texto de las tablas en los siete idiomas. Se conservaron los valores originales de las fuentes y las observaciones numéricas.\n\nSe corrigió la redacción de las ediciones lingüísticas de este artículo para conservar toda su información y su alcance.","title":"Anvisa prohíbe la venta de medicamentos irregulares en Brasil","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/brazil-anvisa-bans-irregular-medicines-october-2026"}],"url":"https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026"},"version":"1"}
